Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Embecta (EMBC) CEO Dev Kurdikar joins Oliver Renick to give an overview of the company and discuss its 2Q earnings. He also talks about the impact of GLP-1 drugs....
Embecta beat Wall Street estimates with its fiscal 2024 Q1 revenue and earnings. The company's full-year outlook, though, came in below consensus estimates....
Embecta Corp.'s stock has dropped 31% since its last publication, and analysis suggests this trend may continue. Despite securing key partnerships and signing multi-year agreements, projected revenue ...
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will...
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will...
PARSIPPANY, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to dis...
Embecta should benefit from the greater need for diabetic services. Viatris is focusing on finding new generics....
Twin beats and raised guidance make for a good day on the market for the diabetes care specialist....
PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management wil...